

1   **Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients**  
2   **receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study**

3  
4   **Authors:**

5   Rémi Goupil, MD, MSc (1)  
6   \*Mehdi Benlarbi, BSc (cand) (2)  
7   William Beaubien-Souigny, MD, PhD (2)  
8   Annie-Claire Nadeau-Fredette, MD, MSc (3)  
9   Debashree Chatterjee, PhD (2)  
10   Guillaume Goyette, PhD (2)  
11   Caroline Lamarche, MD, MSc (3)  
12   Alexander Tom, BSc (4)  
13   \*\*Andrés Finzi, PhD (2, 5, 6)  
14   Rita S. Suri, MD, MSc (2, 5, 7)

15  
16   *on behalf of the Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators*

17  
18   \*co-first author

19   \*\*co-senior author

20  
21   **Affiliations:**

- 22   1. Hôpital du Sacré-Cœur de Montréal, Montréal, QC, Canada  
23   2. Centre de Recherche du CHUM, Montréal, QC, Canada  
24   3. Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada  
25   4. Research Institute of the McGill University Health Center, Montreal, QC, Canada  
26   5. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal,  
27   QC, Canada  
28   6. Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada  
29   7. Department of Medicine, McGill University, Montreal, QC, Canada

30  
31   **Correspondence:**

32   Rita S. Suri  
33   Director, Division of Nephrology  
34   Associate Professor of Medicine  
35   McGill University  
36   Room D05.7166,McGill University Health Centre  
37   1001 Decarie Blvd, Montreal, QC H4A 3J1  
38   T. 514-934-1934 x 35205  
39   F. 514-938-7050  
40   email: [rita.suri@mcgill.ca](mailto:rita.suri@mcgill.ca)

41  
42   **Funding:**

43   This study was funded by a Canadian Institutes of Health Research (CIHR) Rapid Research  
44   COVID-19 funding opportunity. This work was also supported by le Ministère de l'Économie et de  
45   l'Innovation du Québec, Programme de soutien aux organismes de recherche et d'innovation to AF,  
46   by the Fondation du CHUM and by a CIHR Foundation Grant #352417 to AF.

47  
48   **Disclosures :**

49   None.

50 **ABSTRACT**

51

52 **Background**

53 Patients receiving in-center hemodialysis (HD) are at high risk of exposure to SARS-CoV-2 with  
54 high mortality, and response to vaccination is uncertain.

55

56 **Methods**

57 We obtained serial plasma from 58 HD patients and 32 health-care workers (HCW) before and after  
58 vaccination with one dose of the BNT162b2 mRNA vaccine; as well as convalescent plasma from  
59 11 HD patients who survived COVID-19. Anti-RBD (region binding domain of the SARS-CoV-2  
60 Spike protein) IgG and IgM levels were measured by ELISA. Groups were stratified by evidence of  
61 prior SARS-CoV-2 infection.

62

63 **Results**

64 In HD patients without prior SARS-CoV-2, antiRBD levels were significantly lower at 4 and 8  
65 weeks after vaccination, compared to in HCWs after 3 weeks ( $p<0.001$ ), and to convalescent  
66 plasma ( $p=0.002$ ) . Anti-RBD IgG was non-detectable in 29/46 (63%) of HD, compared to 1/16  
67 (6%) of HCWs ( $p<0.0001$ ). No patient with non-detectable levels at 4 weeks developed antiRBD by  
68 8 weeks. In HD patients with prior SARS-CoV-2, mean 8-week anti-RBD IgG levels were similar  
69 to controls at 3 weeks ( $p=0.16$ ), and to convalescent plasma ( $p=0.45$ ). No patients reported  
70 symptoms 7 days after vaccination on a standardized questionnaire.

71

72 **Interpretation**

73 While the BNT162b2 vaccine was well-tolerated in hemodialysis patients, a single dose failed to  
74 elicit a humoral immune response in the majority of SARS-CoV-2 naïve patients even after  
75 prolonged observation. In those with prior SARS-CoV-2 infection, the humoral response after  
76 vaccination was delayed. Whether HD patients develop T-cell responses requires further study.  
77 Until then, we advise the second dose be administered to all HD patients at the recommended 3-  
78 week time interval, and that rigorous SARS-CoV-2 infection prevention and control measures be  
79 continued in dialysis units until vaccine efficacy is proven.

80

81

82 **Introduction**

83  
84 Patients with end-stage kidney disease receiving in-center hemodialysis have been uniquely  
85 vulnerable during the COVID-19 pandemic. Unlike for other people, self-isolation to avoid  
86 exposure to SARS-CoV-2 is impossible. Most HD patients must leave their homes 3 times weekly  
87 to receive their life-saving treatments, often in shared spaces for hours at a time. Once infected, case  
88 fatality rates are 20-30% - 10 times higher than in the general population(1, 2). Advanced age,  
89 multiple comorbidities and blunted immune response likely all contribute to the high COVID-19  
90 death rates in hemodialysis. Some centers have thus prioritized hemodialysis patients for  
91 vaccination.  
92

93 To facilitate wider vaccine distribution during current shortages(3), the National Advisory  
94 Committee on Immunization (NACI) of Canada has recommended delaying the second dose of the  
95 BNT162b2 vaccine from 3 to 16 weeks(4). The reported clinical efficacy of the BNT162b2 was  
96 reported to be >80% at 3 weeks the first dose in a randomized trial(5). However, hemodialysis  
97 patients were not enrolled in this trial(5). Many HD patients have impairments in both humoral and  
98 cellular immune responses(6), and are noted to have lower antibody responses to other vaccines(7).  
99 Thus, whether HD patients develop a robust immune response after vaccination against SARS-  
100 CoV-2 is uncertain.

101 In this context, we sought to determine if short-term antibody response is comparable between  
102 hemodialysis patients and healthcare workers (HCWs) vaccinated with a single dose of the  
103 BNT162b2 mRNA vaccine, and how this compares to antibody responses in dialysis patients who  
104 survived natural infection with SARS-CoV-2.  
105

106 **Methods**

107 We have been following in-center hemodialysis patients in the Réseau Rénal Québécois COVID-19  
108 study since March 2020, with participation of 54 of Quebec's 55 hemodialysis units. Patients  
109 dialyzing in 5 academic centers were recruited for this vaccine substudy. Here we report 8-week  
110 data on the first 58 patients who were vaccinated the week of Jan 26<sup>th</sup> 2021. This study was  
111 approved by the local research ethics board and all patients provided written informed consent.  
112

113 *Protocol:* We obtained clinical data and serial plasma samples from 58 hemodialysis patients before  
114 and every 4 weeks after vaccination with the BNT162b2 (Pfizer-BioNTech) vaccine. All patients  
115 completed a symptoms questionnaire 7 days after vaccination. These patients have been  
116 prospectively followed for symptoms of COVID-19 using a systematic screening questionnaire at  
117 each hemodialysis treatment session since March 200. We also performed weekly surveillance  
118 SARS-CoV-2 testing by PCR of nasopharyngeal swabs from April 2020 to July 2020, and from  
119 October 2020 until now.  
120

121 *Control Patients:* Health-care workers who received the BNT162b2 vaccine served as controls with  
122 plasma obtained before, and 3 weeks post vaccination (12 week samples are pending in this group).  
123 In addition, we obtained convalescent plasma from hemodialysis patient survivors 4-12 weeks after  
124 PCR-confirmed SARS-CoV-2 infection.  
125

126 *Antibody Measures:* IgG antibodies against the receptor binding domain (RBD) of SARS-CoV-2  
127 Spike glycoprotein were assessed in plasma samples using an enzyme-linked immunosorbent assay  
128 and IgG levels reported as relative light units (RLU) normalized to CR3022 mAb, as described(8, 9)  
129

IgG and IgM antibodies against the receptor binding domain (RBD) of SARS-CoV-2 Spike glycoprotein were assessed in plasma samples using an enzyme-linked immunosorbent assay (ELISA)(8, 9). Bovine serum albumin and CR3022 monoclonal antibody (mAb) against SARS-CoV-2 S glycoprotein were used as negative and positive controls, respectively. Anti-RBD IgG and IgM levels were reported as relative light units (RLU) normalized to CR3022 mAb. Seropositive threshold was established as mean RLU from COVID-19 negative plasma obtained from 10 volunteers pre-pandemic plus 3 standard deviations of this mean(8, 9). We have previously shown excellent reliability of this assay in detecting anti-RBD IgG levels in a cross-sectional cohort of infected individuals: anti-RBD IgG levels were detectable with this assay in 85% of infected individuals at 14 days, and in 100% by 53 days after symptom onset(8). Finally, we measured anti-nucleocapsid IgG (anti-N, ELISA, Abbott Architect 1200SR) to rule out new asymptomatic natural infection after vaccination.

*Statistical Analysis:* We stratified groups by past COVID-19 infection (positive PCR to SARS-CoV-2 or positive anti-RBD before vaccination). For one dialysis patient in whom an 8 week sample could not be obtained, the 4-week value was carried forward. Mean RLUs were compared using student's t-test, and the proportion of patients with non-detectable anti-RBD IgG levels were compared with chi-square test. Two-sided p-values of <0.01 were considered significant, considering multiple comparisons.

## Results

Dialysis patients were considerably older than HCWs, with a high rate of diabetes (table 1). No dialysis patient reported symptoms within 7 days after vaccination, and none developed SARS-CoV-2 infection after vaccination as defined by presence of new anti-N antibody or serial PCR. Anti-RBD levels are provided in figure 1 legend.

*SARS-CoV-2 naïve group:* Dialysis patients without prior COVID-19 exhibited significantly lower anti-RBD IgG levels at both 4 and 8 weeks after vaccination, compared to HCWs at 3 weeks (figure 1, panel A), and compared to convalescent plasma from dialysis patient survivors of COVID-19 (figure 1, panel C). The number of dialysis patients with non-detectable antiRBD was 26/46 at 4 weeks (56%, 95% CI = 42-71%), and 29/46 at 8 weeks (63%, 95% CI 49-77%), compared to 1/16 HCWs at 3 weeks (6%, 95% CI 0-18%); (p<0.001 for 4 week comparison, and <0.0001 for 8 week comparison). Importantly, none of the 26 dialysis patients with non-detectable antibodies at 4 weeks had developed detectable antiRBD by 8 weeks. In those with detectable levels at 4 weeks, mean anti-RBD IgG was still significantly lower in dialysis patients than in HCWs ( $14.7 \pm 11.1$  vs.  $44.8 \pm 31.8$  RLU, p=0.0046), and this did not increase by 8 weeks.

*Prior SARS-CoV-2 group:* Twelve dialysis patients had evidence of prior SARS-CoV-2 infection (8 with both positive PCR and anti-RBD, 2 with positive PCR only, and 2 with positive anti-RBD IgG). These 12 patients developed anti-RBD IgG levels 4 weeks after vaccination that were significantly lower than those of HCW controls (figure 1, panel B), but not significantly different than those in convalescent plasma (figure 1, panel C). By 8 weeks, anti-RBD IgG levels in these 12 patients had increased to levels comparable to those in HCWs at 3 weeks (p=0.16). The levels were below detectable levels in 1/12 dialysis patients compared to 0/16 HCWs (p=NS).

*Anti-RBD IgM:* There was no difference in anti-RBD IgM levels at 4 weeks between vaccinated HCW and dialysis patients, either in individuals without prior SARS-CoV-2 (HCW  $4.9 \pm 4.6$  RLU,

180 dialysis  $3.8 \pm 1.1$  RLU,  $p=0.34$ ), or with prior SARS-CoV-2 (HCW  $10.5 \pm 14.8$  RLU, dialysis  $12.1 \pm$   
181  $12.2$  RLU,  $p=0.67$ ).  
182

### 183 Interpretation

184  
185 In a randomized trial, the BNT162b2 vaccine was demonstrated to be >80% clinically effective by  
186 3 weeks after the 1<sup>st</sup> dose in healthy individuals(5). Indeed, all but one of our HCWs developed  
187 anti-RBD IgG within 3 weeks of a single dose of this vaccine. In contrast, we found that COVID-19  
188 naïve patients receiving hemodialysis showed lower anti-RBD IgG levels than healthy controls after  
189 a single dose of the BNT162b2 vaccine, with more than 50% of patients failing to seroconvert at 4  
190 weeks. Importantly, dialysis patients who did not respond at 4 weeks remained non-responders at 8  
191 weeks, arguing against the possibility of a delayed response in these individuals. Humoral response  
192 was better after single dose vaccination in dialysis patients who had been previously infected with  
193 COVID-19, with mean anti-RBD IgG levels similar to healthy controls by 8 weeks.  
194

195 These results suggest that one dose of the BNT162b2 vaccine is insufficient to elicit a robust  
196 humoral immune response in the majority of dialysis patients who have never been previously  
197 exposed to SARS-CoV-2, casting doubt on whether a single dose is effective in this population.  
198 This is consistent with prior studies that show that dialysis patients may require higher or repeated  
199 doses of hepatitis B vaccine to elicit a response(7). We do not know if anti-RBD IgG confers  
200 immunity against SARS-CoV-2, but it is likely a good surrogate as we have previously shown that  
201 anti-RBD IgG response correlates with F<sub>c</sub> mediated effector functions and cellular responses(10),  
202 and all survivors of COVID-19 infection in our study mounted an anti-RBD response 4 to 12 weeks  
203 after infection. Further, while we cannot rule out that vaccinated dialysis patients with undetectable  
204 anti-RBD IgG may have developed protective cellular immune responses, in previous studies,  
205 neutralization, F<sub>c</sub> function, and SARS-CoV-2 specific T cell responses have only been observed in  
206 individuals who elicited RBD-specific antibodies(10, 11). Whether a second dose would induce a  
207 more robust humoral response in dialysis patients without previous SARS-CoV-2 is uncertain. In  
208 another study, 95% (54/56) patients developed detectable anti-Spike IgG levels 30 days after a  
209 second dose of the BNT162b2 vaccine, but we do not know how many of these patients were  
210 previously infected with SARS-CoV-2(12). The latter has an important effect on humoral response  
211 to one vaccine dose, as we have observed: in our study, 91% of dialysis patients (11/12) with prior  
212 SARS-CoV-2 infection developed detectable anti-RBD IgG.  
213

214 Longitudinal follow-up of our cohort is ongoing, and additional patients are being recruited for this  
215 study as vaccinations roll out across the province. Whether humoral responses improve after a  
216 second dose and at what interval, and whether cellular immune responses develop after single or  
217 multiple doses in this population require further study. Tracking the rate symptomatic SARS-CoV-2  
218 infection after vaccination in this and other studies will also aid greatly in our assessment of vaccine  
219 efficacy.  
220

221 Our study has several strengths. We were able to obtain serial plasma samples before and after  
222 vaccination in all patients, and include both healthy individuals and dialysis patients with natural  
223 COVID-19 infection as controls. We were also reliably able to determine history of SARS-CoV-2  
224 infection based on both pre-vaccination anti-RBD IgG and serial PCR data from weekly  
225 surveillance testing. (Pre-vaccination anti-RBD IgG and anti-N has sensitivity of 80% for prior  
226 SARS-CoV-2 detected by historical PCR). We recognize the limitations of this data. We did  
227 measure T cell responses, follow-up is as yet short, and the small sample size does not allow us to  
228 identify patient characteristics predictive of humoral response or determine clinical efficacy.

229

230 While it is reassuring that the BNT162b2 vaccine is well-tolerated in dialysis patients, its efficacy  
231 remains uncertain. A single dose failed to elicit a humoral immune response in the majority of  
232 SARS-CoV-2 naïve patients even after prolonged observation, and in those with prior SARS-CoV-2  
233 infection, the response was delayed. Whether HD patients develop effective T cell responses  
234 requires further study. Until then, we advise the second dose of the BNT162b2 be administered to  
235 all HD patients at the recommended 3-week time interval, and that rigorous SARS-CoV-2 infection  
236 prevention and control measures be continued in dialysis units until vaccine efficacy is proven(13).  
237

## 238 **Acknowledgements**

239  
240 This work is submitted by the authors on behalf of the COVID-19 Study Team of the *Réseau Rénal*  
241 *Québécois*. The authors thank the participants for donating their plasma samples. We are grateful to  
242 our research coordinators, Ms. Norka Rios, Ms. Marie-Line Caron, and Ms. Guylaine Marcotte. We  
243 thank Dr. Nick Bertos and the Research Institute of the McGill University Health Center for sample  
244 processing and storage. RS, RG, ACNF, and WBS are supported by the Fonds de Recherche du  
245 Québec – Santé (FRQS) Clinician-Researcher Awards. AF is the recipient of Canada Research  
246 Chair on Retroviral Entry no. RCHS0235950-232424. This study was funded by a Canadian  
247 Institutes of Health Research (CIHR) Rapid Research COVID-19 funding opportunity. This work  
248 was also supported by le Ministère de l’Économie et de l’Innovation du Québec, Programme de  
249 soutien aux organismes de recherche et d’innovation to AF, by the Fondation du CHUM and by a  
250 CIHR Foundation Grant #352417 to AF.  
251

## 252 **Disclosures :**

253 None.

254

## 255 **Data and Materials**

256  
257 De-identified data is available upon request to the lead author, Rita Suri ([rita.suri@mcgill.ca](mailto:rita.suri@mcgill.ca)).  
258 Further information and requests for reagents should be directed to and will be fulfilled by AF  
259 ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)).  
260  
261  
262  
263  
264

265

## References

- 266 1. Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmeler MH, Jager KJ, et al. COVID-  
267 19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration.  
268 Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant  
269 Association - European Renal Association. 2020;35(11):1973-83.
  - 270 2. Taji L, Thomas D, Oliver MJ, Ip J, Tang Y, Yeung A, et al. COVID-19 in patients undergoing long-  
271 term dialysis in Ontario. CMAJ. 2021;193(8):E278-E84.
  - 272 3. Kadire SR, Wachter RM, Lurie N. Delayed Second Dose versus Standard Regimen for Covid-19  
273 Vaccination. N Engl J Med. 2021;384(9):e28.
  - 274 4. National Advisory Committee on Immunization (NACI). Health Canada.  
<https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html>. Accessed March 23 2021.
  - 275 5. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of  
276 the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
  - 277 6. Knerr K, Futh R, Hemsen P, Mohne W, Heinig A, Kleophas W, et al. Chronic inflammation and  
278 hemodialysis reduce immune competence of peripheral blood leukocytes in end-stage renal failure patients.  
281 Cytokine. 2005;30(3):132-8.
  - 282 7. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin  
283 Microbiol Rev. 2019;32(2).
  - 284 8. Prevost J, Gasser R, Beaudoin-Bussieres G, Richard J, Duerr R, Laumaea A, et al. Cross-Sectional  
285 Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Rep Med. 2020;1(7):100126.
  - 286 9. Beaudoin-Bussieres G, Laumaea A, Anand SP, Prevost J, Gasser R, Goyette G, et al. Decline of  
287 Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio. 2020;11(5).
  - 288 10. Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, et al. A single  
289 BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing  
290 humoral and T cell responses. bioRxiv. 2021:2021.03.18.435972.
  - 291 11. Bartsch YC, Fischinger S, Siddiqui SM, Chen Z, Yu J, Gebre M, et al. Discrete SARS-CoV-2  
292 antibody titers track with functional humoral stability. Nat Commun. 2021;12(1):1018.
  - 293 12. Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral Response to the Pfizer  
294 BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clinical journal of the American  
295 Society of Nephrology : CJASN. 2021.
  - 296 13. Suri RS, Antonseen JE, Banks CA, Clark DA, Davison SN, Frenette CH, et al. Management of  
297 Outpatient Hemodialysis During the COVID-19 Pandemic: Recommendations From the Canadian Society of  
298 Nephrology COVID-19 Rapid Response Team. Can J Kidney Health Dis. 2020;7:2054358120938564.
- 299
- 300

301 **Table 1: Baseline Characteristics**

302

| Variable                                      | Vaccinated, COVID-19 naïve  |                                 | Vaccinated, Prior COVID-19    |                                 | Unvaccinated <sup>a</sup><br>DIALYSIS<br>[Group D3,<br>N=11] |
|---|-----------------------------|---------------------------------|-------------------------------|---------------------------------|--|
|   | HCWs<br>[Group H1,<br>N=16] | DIALYSIS<br>[Group D1,<br>N=46] | HCWs<br>[Group H2,<br>N=16]   | DIALYSIS<br>[Group D2,<br>N=12] |  |
| Age (yrs)                                     | 48 (10.1)<br>[52, 21-59]    | 74.4 (12.4)<br>[77, 41-92]      | 47 (12.8)<br>[46, 23-65]      | 80.3 (9.7)<br>[84, 56-90]       | 65.4 (17.1)<br>[70.5, 35-88]                                 |
| Female sex (N, %)                             | 81                          | 21 (46)                         | 50                            | 7 (58)                          | 6 (55)   |
| Long-term Care (N, %)                         | 0                           | 2 (4)                           | 0                             | 2 (17)                          | 0  |
| Immunosuppressive medications (N, %)          | 0                           | 5 (11)                          | 0                             | 1 (8)                           | 2 (18)   |
| Past Kidney Transplant (N, %)                 | 0                           | 0                               | 0                             | 0                               | 3 (27)   |
| Diabetes (N, %)                               | 0                           | 28 (61)                         | 0                             | 6 (50)                          | 7 (63)   |
| Days since COVID-19 infection <sup>b, c</sup> | n/a                         | n/a                             | 249 (58.97)<br>[266, 116-309] | 276 (30)<br>[285, 192-292]      | 82 (22)<br>[88, 55-121]                                      |
| Days since vaccination                        | 22 (3.29)<br>[21, 16-26]    | 28 (1.5)<br>[28, 26-31]         | 20 (1.85)<br>[21, 17-25]      | 27.5 (2.0)<br>[27, 26-31]       | n/a  |
| Hospitalized for COVID-19                     | n/a                         | n/a                             | n/a                           | n/a                             | 6 (55)   |
| Intensive care                                | n/a                         | n/a                             | n/a                           | n/a                             | 1 (9)  |

303 <sup>a</sup>Defined as PCR positive test in dialysis cohort, and onset of symptoms in HCW cohort

304 <sup>b</sup>For 2/12 dialysis patients, time of infection was unknown as they were diagnosed by serology only.

305 <sup>c</sup>At the time of writing, all patients in this group had survived (min 55 days)




306 Data are presented ad mean (SD), [median, range] unless otherwise specified.

307

308

309 **Figure Legend:**

310  
311 **Figure 1:** Anti-RBD IgG in Dialysis Patients and Health Care Workers. Each bar represents a  
312 different individual. Post-vaccine samples were taken 21 days (range 16-26) after a single dose of  
313 BNT162b2 mRNA vaccination in health-care workers, and after 28 days (range 26-31) and 56 days  
314 (range 54-59) in dialysis patients. Anti-RBD IgG levels were measured using ELISA, subtracting  
315 the signal obtained with bovine serum albumin, and normalized to the signal obtained with CR3022  
316 monoclonal antibody to SARS-CoV-2 in each plate. Dotted line represents the “positive threshold  
317 for detection” of anti-RBD IgG, defined as the mean RLU plus 3 standard deviations from plasma  
318 samples obtained from ten volunteers before the pandemic. RLU = relative light units. **A:** Anti-  
319 RBD IgG levels in COVID-19 naïve vaccinated dialysis patients (n=46) and COVID-19 naïve  
320 vaccinated health care workers (n=16). Group H1:  $42 \pm 32$  RLU at 3 weeks; Group D1:  $7.9 \pm 9.5$   
321 RLU at 4 weeks ( $p=0.0007$  vs. H1) and  $7.1 \pm 7.8$  RLU at 8 weeks ( $p = 0.0006$  vs. H1). No antibody  
322 response was observed in 1/16 (6%) of health-care workers at 3 weeks, and 29/46 (54%) of dialysis  
323 patients at 8 weeks ( $p<0.0001$ ). **B:** Anti-RBD IgG levels in vaccinated dialysis patients (n=12) and  
324 vaccinated health care workers (n=16), each with evidence of prior COVID-19 infection. Group H2:  
325  $196 \pm 41$  RLU at 3 weeks; Group D2:  $108 \pm 90$  at 4 weeks ( $p=0.0031$  vs. H2) and  $139 \pm 127$  RLU  
326 at 8 weeks ( $p=0.155$  vs. H2). **C:** Anti-RBD IgG levels in convalescent plasma obtained from  
327 dialysis patients (n=11) between 4-12 weeks after COVID-19 infection. Group D3:  $105 \pm 79$  [ $p =$   
328  $0.002$  vs. D1 at both 4 and 8 weeks;  $p= NS$  vs. D2 at both 4 and at 8 weeks].  
329

**A****B****C**

**Figure 1: Anti-RBD IgG in Dialysis Patients and Health Care Workers.** Each bar represents a different individual. Post-vaccine samples were taken 21 days (range 16-26) after a single dose of BNT162b2 mRNA vaccination in health-care workers, and after 28 days (range 26-31) and 56 days (range 54-59) in dialysis patients. Anti-RBD IgG levels were measured using ELISA, subtracting the signal obtained with bovine serum albumin, and normalized to the signal obtained with CR3022 monoclonal antibody to SARS-CoV-2 in each plate. Dotted line represents the “positive threshold for detection” of anti-RBD IgG, defined as the mean RLU plus 3 standard deviations from plasma samples obtained from ten volunteers before the pandemic. RLU = relative light units.

**A:** Anti-RBD IgG levels in COVID-19 naïve vaccinated dialysis patients (n=46) and COVID-19 naïve vaccinated health care workers (n=16).

Group H1:  $42 \pm 32$  RLU at 3 weeks;

Group D1:  $7.9 \pm 9.5$  RLU at 4 weeks ( $p=0.0007$  vs. H1);

Group D1:  $7.1 \pm 7.8$  RLU at 8 weeks ( $p = 0.0006$  vs. H1).

No antibody response was observed in 1/16 (6%) of health-care workers at 3 weeks, and 29/46 (54%) of dialysis patients at 8 weeks ( $p<0.0001$ ).

**B:** Anti-RBD IgG levels in vaccinated dialysis patients (n=12) and vaccinated health care workers (n=16), each with evidence of prior COVID-19 infection

Group H2:  $196 \pm 41$  RLU at 3 weeks;

Group D2:  $108 \pm 90$  at 4 weeks ( $p=0.0031$  vs. H2):

$139 \pm 127$  RLU at 8 weeks ( $p=0.155$  vs. H2).

**C:** Anti-RBD IgG levels in convalescent plasma obtained from dialysis patients (n=11) between 4-12 weeks after COVID-19 infection.

Group D3:  $105 \pm 79$  [ $p = 0.002$  vs. D1 at both 4 and 8 weeks;  $p= NS$  vs. D2 at both 4 and at 8 weeks].